Obstetrics and Gynaecology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 1681
  • Item
    Thumbnail Image
    Satisfaction, disappointment and regret surrounding fertility preservation decisions in the paediatric and adolescent cancer population
    Jayasuriya, S ; Peate, M ; Allingham, C ; Li, N ; Gillam, L ; Zacharin, M ; Downie, P ; Moore, P ; Super, L ; Orme, L ; Agresta, F ; Stern, C ; Jayasinghe, Y (SPRINGER/PLENUM PUBLISHERS, 2019-09)
    PURPOSE: With over 80% of paediatric and adolescent cancer patients surviving into adulthood, quality-of-life issues such as future fertility are increasingly important. However, little is known about regret around decisions to pursue or forgo fertility preservation (FP). We investigated the risk of decision regret in families involved in making a FP decision and explored contributive factors. METHODS: Parents and patients ≥ 15 years were invited to participate. Participants completed a 10-item survey, including a validated Decision Regret Scale. Scores ≥ 30 indicated high regret. Free-text response items allowed participants to provide reasons for satisfaction or regret. RESULTS: A total of 108 parents and 30 patients participated. Most (81.4%) reported low regret (mean score 13.7). On multivariate analysis, predictors of low regret included having a FP procedure and a fertility discussion pre-treatment. Most participants believed that FP offers hope for future fertility. Some reported dissatisfaction with the process of decision-making. CONCLUSION: Overall levels of regret in the study population were low, with factors associated with quality, timely discussion and belief in the success of FP technology being predictors of low regret. However, dissatisfaction with the decision-making process itself revealed that refinements to the programme are required to meet families' needs.
  • Item
    Thumbnail Image
    Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?
    Nahata, L ; Woodruff, TK ; Quinn, GP ; Meacham, LR ; Chen, D ; Appiah, LC ; Finlayson, C ; Orwig, KE ; Laronda, MM ; Rowell, EE ; Anazodo, A ; Frias, O ; Rios, JS ; Whiteside, S ; Gomez-Lobo, V ; Dwiggins, M ; Childress, KJ ; Hoefgen, HR ; Levine, JM ; Jayasinghe, Y ; Moravek, M (SPRINGER/PLENUM PUBLISHERS, 2020-06)
  • Item
    Thumbnail Image
    A View from the past into our collective future: the oncofertility consortium vision statement
    Woodruff, TK ; Ataman-Millhouse, L ; Acharya, KS ; Almeida-Santos, T ; Anazodo, A ; Anderson, RA ; Appiah, L ; Bader, J ; Becktell, K ; Brannigan, RE ; Breech, L ; Bourlon, MT ; Bumbuliene, Z ; Burns, K ; Campo-Engelstein, L ; Campos, JR ; Centola, GM ; Chehin, MB ; Chen, D ; De Vos, M ; Duncan, FE ; El-Damen, A ; Fair, D ; Famuyiwa, Y ; Fechner, PY ; Fontoura, P ; Frias, O ; Gerkowicz, SA ; Ginsberg, J ; Gracia, CR ; Goldman, K ; Gomez-Lobo, V ; Hazelrigg, B ; Hsieh, MH ; Hoyos, LR ; Hoyos-Martinez, A ; Jach, R ; Jassem, J ; Javed, M ; Jayasinghe, Y ; Jeelani, R ; Jeruss, JS ; Kaul-Mahajan, N ; Keim-Malpass, J ; Ketterl, TG ; Khrouf, M ; Kimelman, D ; Kusuhara, A ; Kutteh, WH ; Laronda, MM ; Lee, JR ; Lehmann, V ; Letourneau, JM ; McGinnis, LK ; McMahon, E ; Meacham, LR ; Mijangos, MFV ; Moravek, M ; Nahata, L ; Ogweno, GM ; Orwig, KE ; Pavone, ME ; Peccatori, FA ; Pesce, RI ; Pulaski, H ; Quinn, G ; Quintana, R ; Quintana, T ; de Carvalho, BR ; Ramsey-Goldman, R ; Reinecke, J ; Reis, FM ; Rios, J ; Rhoton-Vlasak, AS ; Rodriguez-Wallberg, KA ; Roeca, C ; Rotz, SJ ; Rowell, E ; Salama, M ; Saraf, AJ ; Scarella, A ; Schafer-Kalkhoff, T ; Schmidt, D ; Senapati, S ; Shah, D ; Shikanov, A ; Shnorhavorian, M ; Skiles, JL ; Smith, JF ; Smith, K ; Sobral, F ; Stimpert, K ; Su, HI ; Sugimoto, K ; Suzuki, N ; Thakur, M ; Victorson, D ; Viale, L ; Vitek, W ; Wallace, WH ; Wartella, EA ; Westphal, LM ; Whiteside, S ; Wilcox, LH ; Wyns, C ; Xiao, S ; Xu, J ; Zelinski, M (SPRINGER/PLENUM PUBLISHERS, 2021-01)
    PURPOSE: Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium. METHODS: The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process. RESULTS: This interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity. CONCLUSION: The goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future.
  • Item
    Thumbnail Image
    Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion
    Salama, M ; Woodruff, TK (SPRINGER/PLENUM PUBLISHERS, 2021-01)
    PURPOSE: The main objective of Repro-Can-OPEN Study Part 2 is to learn more about oncofertility practices in optimum resource settings to provide a roadmap to establish oncofertility best practice models. METHODS: As an extrapolation for oncofertility best practice models in optimum resource settings, we surveyed 25 leading and well-resourced oncofertility centers and institutions from the USA, Europe, Australia, and Japan. The survey included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer. RESULTS: All surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed three major characteristics of oncofertility practice in optimum resource settings: (1) strong utilization of sperm freezing, egg freezing, embryo freezing, ovarian tissue freezing, gonadal shielding, and fractionation of chemo- and radiotherapy; (2) promising utilization of GnRH analogs, oophoropexy, testicular tissue freezing, and oocyte in vitro maturation (IVM); and (3) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cell reproductive technology as they are still in preclinical or early clinical research settings. Proper technical and ethical concerns should be considered when offering advanced and experimental oncofertility options to patients. CONCLUSIONS: Our Repro-Can-OPEN Study Part 2 proposed installing specific oncofertility programs for common cancers in optimum resource settings as an extrapolation for best practice models. This will provide efficient oncofertility edification and modeling to oncofertility teams and related healthcare providers around the globe and help them offer the best care possible to their patients.
  • Item
    Thumbnail Image
    Predicting successful sperm retrieval in transfeminine adolescents after testicular biopsy
    Peri, A ; Ahler, A ; Gook, D ; O'Connell, MA ; Bourne, H ; Nightingale, M ; Telfer, M ; Jayasinghe, Y ; Pang, KC (SPRINGER/PLENUM PUBLISHERS, 2021-10)
    PURPOSE: Increasing numbers of transgender adolescents are receiving gender-affirming treatments (GAT). Given GAT can impair reproductive function, clinical guidelines advise prior counselling regarding fertility preservation (FP). For transgender adults assigned male at birth, FP is usually achieved via a masturbatory sample and sperm cryopreservation. This is less straightforward in transgender adolescents, since they may not be developmentally ready to masturbate and/or masturbation may cause unacceptable gender dysphoria. Testicular biopsy represents an alternative method for sperm retrieval in these adolescents, but for those in early/mid puberty, it is difficult to predict whether sperm will be found. The purpose of this study was therefore to identify factors that predict successful sperm retrieval for cryopreservation via testicular biopsy. METHODS: A retrospective cohort study was undertaken at a tertiary-referral pediatric gender service. Subjects were included if they'd received a testicular biopsy in association with the commencement of GAT between 2010 and 2019. The primary outcome measure was successful sperm retrieval, and potential predictors included age, testicular volume and serum testosterone, LH and FSH levels. RESULTS: Of 25 subjects who received a biopsy prior to starting any GAT, 17 had successful sperm retrieval. While age, testosterone, LH and FSH levels showed minimal differences, testicular volume was significantly higher in those with successful sperm retrieval, and a threshold of ≥ 10 mL showed 92% sensitivity and 71% specificity in predicting successful retrieval. An additional 6 patients received a biopsy after starting puberty suppression and before commencement of oestrogen, and one of these individuals had sperm successfully retrieved despite > 2 years of regular puberty suppression. CONCLUSION: These findings suggest that testicular volume is most useful in predicting successful sperm retrieval following testicular biopsy in transgender adolescents and are likely to be of relevance to other young people undertaking FP, including those with cancer.
  • Item
    Thumbnail Image
    Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
    Salama, M ; Lambertini, M ; Christianson, MS ; Jayasinghe, Y ; Anazodo, A ; De Vos, M ; Amant, F ; Stern, C ; Appiah, L ; Woodard, TL ; Anderson, RA ; Westphal, LM ; Leach, RE ; Rodriguez-Wallberg, KA ; Patrizio, P ; Woodruff, TK (SPRINGER/PLENUM PUBLISHERS, 2022-02)
    PURPOSE: As a further step to elucidate the actual diverse spectrum of oncofertility practices for breast cancer around the globe, we present and discuss the comparisons of oncofertility practices for breast cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II. METHODS: We surveyed 39 oncofertility centers including 14 in limited resource settings from Africa, Asia & Latin America (Repro-Can-OPEN Study Part I), and 25 in optimum resource settings from the United States, Europe, Australia and Japan (Repro-Can-OPEN Study Part II). Survey questions covered the availability of fertility preservation and restoration options offered to young female patients with breast cancer as well as the degree of utilization. RESULTS: In the Repro-Can-OPEN Study Part I & II, responses for breast cancer and calculated oncofertility scores showed the following characteristics: (1) higher oncofertility scores in optimum resource settings than in limited resource settings especially for established options, (2) frequent utilization of egg freezing, embryo freezing, ovarian tissue freezing, GnRH analogs, and fractionation of chemo- and radiotherapy, (3) promising utilization of oocyte in vitro maturation (IVM), (4) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, and stem cells reproductive technology as they are still in preclinical or early clinical research settings, (5) recognition that technical and ethical concerns should be considered when offering advanced and innovative oncofertility options. CONCLUSIONS: We presented a plausible oncofertility best practice model to guide oncofertility teams in optimizing care for breast cancer patients in various resource settings.
  • Item
    Thumbnail Image
    Editorial: Fertility preservation in the pediatric population
    Chattha, AJJ ; Salama, M ; Jayasinghe, Y (Frontiers Media S.A., 2023-02-16)
    The Frontiers in Endocrinology Research Topic on fertility preservation in children invited authors from across the globe to participate in the dissemination of knowledge and awareness regarding the best fertility preservation principles in the pediatric population. Although long considered a problem only in adults and post pubertal individuals undergoing cancer therapy, assisted reproductive technologies have rapidly advanced to include ovarian and testicular tissue preservation. This now allows prepubertal patients and families who were previously excluded from fertility conversations, to be included in these profoundly important discussions, which may provide hope for future attempts at parenthood (1). Fertility preservation is now considered for any medical condition requiring gonadotoxic treatment with curative intent, as well as those causing premature gonadal decline. This means that oncofertility care is now being rapidly expanded to include children with non-oncologic conditions affecting fertility such as genetic, rheumatologic, nephrologic disease, and hematologic conditions requiring bone marrow transplant, as well as the transgender population (1). However, many knowledge gaps exist in the pediatric population, which this Research Topic sought to address.
  • Item
    Thumbnail Image
    Pediatric oncofertility care in limited versus optimum resource settings: results from 39 surveyed centers in Repro-Can-OPEN Study Part I & II
    Salama, M ; Nahata, L ; Jayasinghe, Y ; Gomez-Lobo, V ; Laronda, MM ; Moravek, MB ; Meacham, LR ; Christianson, MS ; Lambertini, M ; Anazodo, A ; Quinn, GP ; Woodruff, TK (SPRINGER/PLENUM PUBLISHERS, 2023-03)
    PURPOSE: As a secondary report to elucidate the diverse spectrum of oncofertility practices for childhood cancer around the globe, we present and discuss the comparisons of oncofertility practices for childhood cancer in limited versus optimum resource settings based on data collected in the Repro-Can-OPEN Study Part I & II. METHODS: We surveyed 39 oncofertility centers including 14 in limited resource settings from Africa, Asia, and Latin America (Repro-Can-OPEN Study Part I), and 25 in optimum resource settings from the USA, Europe, Australia, and Japan (Repro-Can-OPEN Study Part II). Survey questions covered the availability of fertility preservation and restoration options offered in case of childhood cancer as well as their degree of utilization. RESULTS: In the Repro-Can-OPEN Study Part I & II, responses for childhood cancer and calculated oncofertility scores showed the following characteristics: (1) higher oncofertility scores in optimum resource settings than in limited resource settings for ovarian and testicular tissue cryopreservation; (2) frequent utilization of gonadal shielding, fractionation of anticancer therapy, oophoropexy, and GnRH analogs; (3) promising utilization of oocyte in vitro maturation (IVM); and (4) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cells reproductive technology as they are still in preclinical or early clinical research settings. CONCLUSIONS: Based on Repro-Can-OPEN Study Part I & II, we presented a plausible oncofertility best practice model to help optimize care for children with cancer in various resource settings. Special ethical concerns should be considered when offering advanced and innovative oncofertility options to children.
  • Item
    Thumbnail Image
    Ovarian stimulation and oocyte cryopreservation in females and transgender males aged 18 years or less: a systematic review
    Slonim, M ; Peate, M ; Merigan, K ; Lantsberg, D ; Anderson, RA ; Stern, K ; Gook, D ; Jayasinghe, Y (FRONTIERS MEDIA SA, 2023-06-19)
    BACKGROUND: Fertility preservation is an important healthcare focus in the paediatric and adolescent population when gonadotoxic treatments are required. Ovarian stimulation (OS) resulting in oocyte cryopreservation is a well-established fertility preservation option in the adult population. It's utility, however, is little known in young patients. The purpose of this review was to synthesise the available literature on OS in patients ≤18 years old, to identify gaps in current research and provide suggestions for future research directions. METHODS: Using PRISMA guidelines, a systematic review of the literature was performed for all relevant full-text articles published in English in Medline, Embase, the Cochrane Library and Google Scholar databases. The search strategy used a combination of subject headings and generic terms related to the study topic and population. Two reviewers independently screened studies for eligibility, extracted data and assessed the risk of bias. Characteristics of the studies, objectives and key findings were extracted and summarised in a narrative synthesis. RESULTS: Database search and manual review identified 922 studies, 899 were eliminated based on defined exclusion criteria. Twenty-three studies were included and comprised 468 participants aged ≤18 years who underwent OS (median 15.2, range 7-18 years old). Only three patients were premenarchal, and four patients were on treatment to suppress puberty. Patients had OS for a broad range of indications including oncology treatment, transgender care and Turner syndrome. A total of 488 cycles of OS were completed, with all but 18 of these cycles (96.3%) successfully resulting in cryopreserved mature oocytes (median 10 oocytes, range 0-35). Fifty-three cycles (9.8%) were cancelled. Complications were rare (<1%). One pregnancy was reported from a female who had OS aged 17 years old. CONCLUSION: This systematic review demonstrates that OS and oocyte cryopreservation is achievable in young females however there are only a few cases in the literature describing OS in premenarcheal children or those who have suppressed puberty. There is little proof that OS can lead to pregnancy in adolescents, and no proof that this can be achieved in premenarchal girls. Therefore it should be regarded as an innovative procedure for adolescents and experimental for premenarcheal girls. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=265705, identifier CRD42021265705.
  • Item
    No Preview Available
    Female reproductive health in pediatric, adolescent, and young adult cancer survivors
    Hoefgen, HRR ; Benoit, J ; Chan, S ; Jayasinghe, Y ; Lustberg, M ; Pohl, V ; Saraf, A ; Schmidt, D ; Appiah, LC (Wiley, 2023-09)
    An estimated 500,000 cancer survivors of reproductive age in the United States will live to experience the long-term consequences of cancer treatment. Therefore, a focused aspect of cancer care has appropriately shifted to include quality of life in survivorship. Infertility is a late effect of therapy that affects 12% of female survivors of childhood cancer receiving any cancer treatment in large cohort studies and results in a 40% decreased likelihood of pregnancy in young adults of ages 18-39 years. Nonfertility gynecologic late effects such as hypoestrogenism, radiation-induced uterine and vaginal injury, genital graft-versus-host disease after hematopoietic stem cell transplant, and sexual dysfunction also significantly affect quality of life in survivorship but are underdiagnosed and require consideration. Several articles in the special edition "Reproductive Health in Adolescent and Young Adult Cancer Survivorship" address infertility, genital graft-versus-host disease, and psychosexual functioning in survivorship. This review article focuses on other adverse gynecologic outcomes of cancer therapies including hypogonadism and hormone replacement therapy, radiation-induced uterovaginal injury, vaccination and contraception, breast and cervical cancer screening, and pregnancy considerations in survivorship.